查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球週边血管血栓管理介入市场 -2023-2030
市场调查报告书
商品编码
1374797

全球週边血管血栓管理介入市场 -2023-2030

Global Peripheral Vascular Clot Management Interventions Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

早期发现和治疗血栓可以显着降低中风和血管疾病引起的死亡率。血液凝固是防止血管受伤时过度出血的重要过程。血小板（一种血球）和血浆中的蛋白质（血液的液体部分）共同作用，透过在伤口上形成凝块来止血。

此外，全球週边血管血栓管理干预市场受到多种因素的推动，例如全球心血管疾病发病率上升、血栓管理设备的技术进步、此类尖端技术的不断发展以及其他将有助于该市场在未来几年增长的因素。预测期内有雅培实验室、爱德华生命科学公司、美敦力公司、泰利福医疗等重要关键参与者。

动力学

血管疾病盛行率上升

血管疾病盛行率的上升是预测期内帮助市场成长的关键因素之一。週边动脉疾病（PAD）和深部静脉血栓（DVT）等疾病的盛行率一直在上升，这主要是由于吸烟、肥胖和久坐行为等生活方式因素造成的。这推动了对血栓管理干预措施的需求。

例如，根据疾病管制与预防中心更新的情况说明书，受深部静脉栓塞 (DVT) 或肺栓塞 (PE) 影响的确切人数尚不清楚，儘管在美国每年可能有多达 90 万人受到影响。状态。

老年人口发病率增加

由于与年龄相关的因素，例如活动能力下降、慢性健康状况（例如高血压、糖尿病、心臟病）以及可能正在服用的药物，老年人通常面临更高的血栓形成风险。例如，世界卫生组织 (WHO) 估计，到 2050 年，全球 60 岁或以上的人口将从 2020 年的 10 亿增加到 21 亿。

此外，一些资料和研究表明，60 岁或以上的人群是深部静脉血栓形成（当体内一根或多根深部静脉中形成血块时）的最重要的独立危险因素。因此，老年人口的增加加上他们的血栓形成负担预计将创造对血栓管理设备的需求，从而推动分析期间的市场成长。

设备成本高

週边血管血栓管理介入装置可能价格昂贵，这可能成为某些患者使用的障碍。这些设备的高成本是由于程序的复杂性和设备中使用的先进技术。

例如，血管内动脉瘤修復支架移植物的成本非常高，这可能成为预测期内阻碍市场成长的限制因素。动脉瘤相关后续干预的住院费用中位数为 22,023 美元（IQR，13,177 美元至 47,752 美元），而非动脉瘤相关后续干预费用中位数为 19,007 美元（IQR，8708 美元至 33,301 美元）。

有关此报告的更多详细资讯 索取样品

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按指示显示的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 血管疾病盛行率上升
      • 老年人口发病率增加
    • 限制
      • 设备成本高
    • 机会
      • 新兴市场产品发布数量增加
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 导管
  • 血管内动脉瘤修补覆膜支架
  • 下腔静脉过滤器
  • 斑块修饰装置
  • 血流动力学流量改变装置
  • 其他週边血管装置

第 8 章：依指示

  • 深部静脉血栓 (DVT)
  • 肺动脉栓塞

第 9 章：最终用户

  • 医院
  • 门诊手术中心
  • 专科诊所

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Abbott Laboratories
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Edward Lifesciences Corporation.
  • Medtronic Inc.
  • Teleflex Medical.
  • Boston Scientific Corporation.
  • Biotronik
  • Merit
  • B. Braun SE
  • Terumo Corporation
  • Penumbra Inc

第 13 章：附录

简介目录
Product Code: MD7213

Overview

Early detection and treatment of blood clots can significantly reduce the death rate due to stroke and vascular diseases. Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Platelets (a type of blood cell) and proteins in your plasma (the liquid part of the blood) work together to stop the bleeding by forming a clot over the injury.

Furthermore, the global peripheral vascular clot management interventions market is driven by various factors like the rising global incidence of cardiovascular diseases, technological advancements in clot management devices, continuous development of such cutting-edge technologies and others that will help this market to grow during the forecast period having significant key players like Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc, Teleflex Medical and others.

Dynamics

Rising Prevalence of Vascular Diseases

The rise in the prevalence of vascular diseases is one of the key factors that helps the market to grow during the forecast period. The prevalence of conditions like peripheral artery disease (PAD) and deep vein thrombosis (DVT) has been on the rise, primarily due to lifestyle factors like smoking, obesity, and sedentary behaviour. This drives the need for clot management interventions.

For instance, according to the Centers for Disease Control and Prevention updated factsheet The precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States.

Increase in the Incidence of Geriatric Population

Older individuals often face a higher risk of developing blood clots due to age-related factors such as reduced mobility, chronic health conditions (e.g., hypertension, diabetes, heart disease), and medications they may be taking. For instance, The World Health Organization (WHO) estimates that by 2050, there will be 2.1 billion people worldwide who are 60 years of age or older, up from 1 billion in 2020.

In addition, several sources and research show that the population aged 60 years or more is the foremost independent risk factor for deep vein thrombosis (when a blood clot forms in one or more of the deep veins in the body). Thus, the increasing geriatric population coupled with the burden of thrombosis among them is expected to create demand for clot management devices, thereby driving the market growth over the analysis period.

High Cost of Devices

Peripheral vascular clot management intervention devices can be costly, which can be a barrier to access for some patients. The high cost of these devices is due to the complexity of the procedures and the advanced technology used in the devices.

For instance, endovascular aneurysm repair stent grafts costs are very high which can be a restraint factor that hamper the market growth during the forecast period. The median cost of hospitalization for aneurysm-related subsequent intervention was $22,023 (IQR, $13,177-$47,752), compared with a median non-aneurysm-related subsequent intervention cost of $19,007 (IQR, $8708-$33,301).

For more details on this report Request for sample

Segment Analysis

The global peripheral vascular clot management interventions market is segmented based on device type, indication, end-user and region.

The Catheters Segment From the Device Type Segment Accounted For Approximately 41.7% of Peripheral Vascular Clot Management Interventions Share

The catheters segment from the device type segment accounted for 41.7% and it is expected to be dominated during the forecast period. The catheters are used to send clot-dissolving medicine to the DVT. This can help break up the clot or else the healthcare provider might use small tools to help break up the clot.

Catheter-directed thrombolysis treats vascular blockages and improves blood flow by dissolving abnormal blood clots. A blood clot, or thrombus, can block off blood supply to certain parts of the body and cause serious damage. Catheter-directed thrombolysis uses X-ray imaging and a catheter to guide special medication or a medical device to the site of a blood clot to dissolve the blockage.

For instance, in September 2021 Boston Scientific Corporation stated an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like novel treatment, new device launches, FDA Clearance, advanced healthcare infrastructure, Robust Healthcare Spending and other factors that help this region to grow during the forecast period.

For instance, in February 2023 Woodland Heights Medical Center is the first in the Lufkin/Nacogdoches area to utilize a new treatment for pulmonary embolism and deep vein thrombosis. It is the first mechanical thrombectomy device FDA indicated and purpose-built for this treatment.

Deep vein thrombosis (DVT) typically occurs when a blood clot forms in the legs and pulmonary embolism (PE) occurs when a part of the clot breaks off, travels through the bloodstream and causes a blockage of blood flow to the lungs. The blockage of blood flow results in right heart strain as the right ventricle is unable to push blood past the clot. In severe cases, right heart failure may occur leading to a fatal event.

Moreover, in January 2023 Penumbra, Inc. a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's novel Lightning Intelligent Aspiration technology, now with dual clot detection algorithms.

Competitive Landscape

The major global players in the market include: Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc., Teleflex Medical, Boston Scientific Corporation., Biotronik, Merit, B. Braun SE, Terumo Corporation, Penumbra Inc and among others.

COVID-19 Impact Analysis

During the early phases of the pandemic, many conventional peripheral vascular clot management treatments were postponed or cancelled as healthcare resources were redirected to treat COVID-19 patients. As a result, procedure numbers and the market for associated medical devices and medications declined in the short term.

Also, the mysterious clots in COVID-19 patients may be due to the binding of the SARS-CoV-2 spike protein with the ACE2 receptor in blood vessel endothelial cells. This interaction has caused vasoconstriction and activation of the intrinsic coagulation pathway, leading to the formation of blood clots. The pathogenesis of SARS-CoV-2 and the role of ACE2 in RAS are also considered.

Key Developments

  • In March 2023 SMT stated that it has been selected as the exclusive distributor of Penumbra's peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Under the terms of the agreement, SMT will provide healthcare providers with Penumbra's latest Indigo System portfolio, including CATTM RX, which recently received India CDSCO (Central Drug Standard Control Organization) approval, and Lightning technologies, upon regulatory approval, to address conditions such as coronary thrombosis, venous thrombosis, arterial thrombosis and pulmonary embolism.
  • In March 2021 Penumbra, Inc., a global healthcare company focused on innovative therapies, stated U.S. commercial availability of the Indigo System Lightning 7. Lightning 7 expands Penumbra's offering of the Indigo Aspiration System with Intelligent Aspiration for mechanical thrombectomy and is designed for single-session arterial thrombus removal.

Why Purchase the Report?

  • To visualize the global peripheral vascular clot management interventions market segmentation based on device type, indication, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global peripheral vascular clot management interventions market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global peripheral vascular clot management interventions market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Vascular Diseases
      • 4.1.1.2. Increase in the Incidence of Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Devices
    • 4.1.3. Opportunity
      • 4.1.3.1. Rise in the Product Launches in Emerging Markets
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Catheters*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Endovascular Aneurysm Repair Stent Grafts
  • 7.4. Inferior Vena Cava Filters
  • 7.5. Plaque Modification Devices
  • 7.6. Hemodynamic Flow Alteration Device
  • 7.7. Other Peripheral Vascular Devices

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Deep Vein Thrombosis (DVT) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pulmonary Artery Embolism

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Specialty Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Edward Lifesciences Corporation.
  • 12.3. Medtronic Inc.
  • 12.4. Teleflex Medical.
  • 12.5. Boston Scientific Corporation.
  • 12.6. Biotronik
  • 12.7. Merit
  • 12.8. B. Braun SE
  • 12.9. Terumo Corporation
  • 12.10. Penumbra Inc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us